Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 3/2018

01-03-2018 | Review

Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis

Authors: Bonnie Williams, Anak Dharmapatni, Tania Crotti

Published in: Inflammation Research | Issue 3/2018

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that results in both local and systemic bone erosion, causing significant joint deformities and functional disability. The increased number of synovial fibroblasts, inflammatory cells and osteoclasts in RA is associated with reduced apoptosis in these cells. The ability to modulate the cell proliferation or death (particularly apoptosis) is recognised for its immense therapeutic potential. Identifying new therapeutics to assist in stimulating apoptosis within the synovial joints therefore may be beneficial in reducing inflammation and bone loss in RA patients. In this review, the roles of anti-apoptotic proteins that are upregulated in RA synovial joints will be discussed in relation to their actions on bone destruction and inflammation. Evidence recently published suggests that intracellular apoptotic inhibitory molecules can be targeted by current or new therapeutics to reduce joint damage in RA. However, the therapeutics that target these molecules are yet to reach clinical trial stages. Even so it is evident that understanding the upregulation of anti-apoptotic molecules in RA is required to improve treatments currently available for RA patients.
Literature
1.
Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17(5):729–752.CrossRefPubMed
2.
Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NF-kappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30(2):340–6.CrossRefPubMed
3.
4.
Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology. 2003;42(1):123–34.CrossRefPubMed
5.
Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998;152(4):943–51.PubMedPubMedCentral
6.
Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1(2):102–10.CrossRefPubMed
7.
Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001;159(5):1689–99.CrossRefPubMedPubMedCentral
8.
Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(5):1003–12.CrossRefPubMed
9.
10.
Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, et al. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther. 2009;11(1):R13.CrossRefPubMedPubMedCentral
11.
12.
Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science. 1995;268(5209):429–31.CrossRefPubMed
13.
Ethell DW, Buhler LA. Fas ligand-mediated apoptosis in degenerative disorders of the brain. J Clin Immunol. 2003;23(6):439–46.CrossRefPubMed
14.
Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol. 2002;2(7):527–35.CrossRefPubMed
15.
Parida JR, Misra DP, Wakhlu A, Agarwal V. Is non-biological treatment of rheumatoid arthritis as good as biologics? World J Orthop. 2015;6(2):278–83.CrossRefPubMedPubMedCentral
16.
Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology. 2001;40(4):367–74.CrossRefPubMed
17.
Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol. 2001;28(8):1800–8.PubMed
18.
Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology. 2010;49(5):862–75.CrossRefPubMed
19.
Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16–25.PubMedPubMedCentral
20.
Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102(2):322–8.CrossRefPubMedPubMedCentral
21.
Metzstein MM, Stanfield GM, Horvitz HR. Genetics of programmed cell death in C. elegans: past, present and future. Trends Genet. 1998;14(10):410–6.CrossRefPubMed
22.
23.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487–501.CrossRefPubMed
24.
25.
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579–88.PubMedPubMedCentral
26.
Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23(16):2861–74.CrossRefPubMed
27.
Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–56.CrossRefPubMed
28.
Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 2001;276(10):7320–6.CrossRefPubMed
29.
Hill MM, Adrain C, Duriez PJ, Creagh EM, Martin SJ. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J. 2004;23(10):2134–45.CrossRefPubMedPubMedCentral
30.
31.
Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3-3 not BCL-X(L). Cell. 1996;87(4):619–28.CrossRefPubMed
32.
Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64(20):7183–90.CrossRefPubMed
33.
Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410(6828):549–54.CrossRefPubMed
34.
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391(6662):43–50.CrossRefPubMed
35.
36.
Perlman H, Liu H, Georganas C, Koch AE, Shamiyeh E, Haines GK 3rd, et al. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. Arthritis Rheum. 2001;44(12):2899–908.CrossRefPubMed
37.
38.
Perlman H, Georganas C, Pagliari LJ, Koch AE, Haines K 3rd, Pope RM. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol. 2000;164(10):5227–35.CrossRefPubMed
39.
Liu H, Huang Q, Shi B, Eksarko P, Temkin V, Pope RM. Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006;54(10):3174–81.CrossRefPubMed
40.
Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005;328(3):709–20.CrossRefPubMed
41.
Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages require constitutive NF-kappaB activation to maintain A1 expression and mitochondrial homeostasis. Mol Cell Biol. 2000;20(23):8855–65.CrossRefPubMedPubMedCentral
42.
Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK 3rd, Pope RM. Rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum. 2001;44(1):21–30.CrossRefPubMed
43.
Matsumoto S, Muller-Ladner U, Gay RE, Nishioka K, Gay S. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol. 1996;23(8):1345–52.PubMed
44.
Franz JK, Pap T, Hummel KM, Nawrath M, Aicher WK, Shigeyama Y, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum. 2000;43(3):599–607.CrossRefPubMed
45.
Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. Curr Pharm Des. 2005;11(5):569–80.CrossRefPubMed
46.
Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med. 1999;190(11):1679–88.CrossRefPubMedPubMedCentral
47.
Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis. 2002;61(10):934–6.CrossRefPubMedPubMedCentral
48.
Willems F, Amraoui Z, Vanderheyde N, Verhasselt V, Aksoy E, Scaffidi C, et al. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 2000;95(11):3478–82.PubMed
49.
Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3(6):401–10.CrossRefPubMed
50.
51.
Bai S, Liu H, Chen KH, Eksarko P, Perlman H, Moore TL, et al. NF-kappaB-regulated expression of cellular FLIP protects rheumatoid arthritis synovial fibroblasts from tumor necrosis factor alpha-mediated apoptosis. Arthritis Rheum. 2004;50(12):3844–55.CrossRefPubMed
52.
53.
Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther. 2005;7(2):R349–R58.CrossRefPubMedPubMedCentral
54.
Newmeyer DD, Bossy-Wetzel E, Kluck RM, Wolf BB, Beere HM, Green DR. Bcl-xL does not inhibit the function of Apaf-1. Cell Death Differ. 2000;7(4):402–7.CrossRefPubMed
55.
Zhang Q, Badell IR, Schwarz EM, Boulukos KE, Yao Z, Boyce BF, et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 2005;52(9):2708–18.CrossRefPubMed
56.
Hutcheson J, Perlman H. BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention. Oncogene. 2008;27(Suppl 1):S168–75.CrossRefPubMedPubMedCentral
57.
Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, et al. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009;182(12):7482–9.CrossRefPubMed
58.
Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 2013;12(9):1691–700.CrossRefPubMed
59.
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–99.CrossRefPubMedPubMedCentral
60.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.CrossRefPubMedPubMedCentral
61.
Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert opinion on investigational drugs. 2011;20(10):1397–411.CrossRefPubMedPubMedCentral
62.
Billard C. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia. Mol Cancer Res. 2012;10(6):673–6.CrossRefPubMed
63.
Hurez VJ, Ramanujan S, Shoda LKM, Wennerberg LG, Michelson SG, Deframoux N. Treatment of rheumatoid arthritis with FLIP antagonists. United States patent application publication. 2005:pp. 1–16.
64.
Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388(6639):300–4.CrossRefPubMed
65.
Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17(8):2215–23.CrossRefPubMedPubMedCentral
66.
Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34 + 38-cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011;16(1):67–74.CrossRefPubMedPubMedCentral
67.
Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, et al. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013;36(3):239–43.CrossRefPubMed
68.
Mahendran S, Badami S, Ravi S, Thippeswamy BS, Veerapur VP. Synthesis and evaluation of analgesic and anti-inflammatory activities of most active free radical scavenging derivatives of embelin-A structure-activity relationship. Chem Pharm Bull (Tokyo). 2011;59(8):913–9.CrossRef
69.
Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004;47(10):2430–40.CrossRefPubMed
70.
Chen J, Nikolovska-Coleska Z, Wang G, Qiu S, Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg Med Chem Lett. 2006;16(22):5805–8.CrossRefPubMed
71.
Xu M, Cui J, Fu H, Proksch P, Lin W, Li M. Embelin derivatives and their anticancer activity through microtubule disassembly. Planta Med. 2005;71(10):944–8.CrossRefPubMed
72.
Park N, Baek HS, Chun YJ. Embelin-induced apoptosis of human prostate cancer cells is mediated through modulation of akt and beta-catenin signaling. PLoS One. 2015;10(8):e0134760.CrossRefPubMedPubMedCentral
73.
Peng M, Huang B, Zhang Q, Fu S, Wang D, Cheng X, et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett. 2014;354(2):407–16.CrossRefPubMed
74.
Hu R, Yang Y, Liu Z, Jiang H, Zhu K, Li J, et al. The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation. Tumour Biol. 2015;36(2):769–77.CrossRefPubMed
75.
Wang DG, Sun YB, Ye F, Li W, Kharbuja P, Gao L, et al. Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. Mol Cell Biochem. 2014;386(1–2):143–52.CrossRefPubMed
76.
Park SY, Lim SL, Jang HJ, Lee JH, Um JY, Kim SH, et al. Embelin induces apoptosis in human glioma cells through inactivating NF-kappaB. J Pharmacol Sci. 2013;121(3):192–9.CrossRefPubMed
77.
Kalyan Kumar G, Dhamotharan R, Kulkarni NM, Mahat MY, Gunasekaran J, Ashfaque M. Embelin reduces cutaneous TNF-alpha level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur J Pharmacol. 2011;662(1–3):63–9.CrossRefPubMed
78.
Thippeswamy BS, Mahendran S, Biradar MI, Raj P, Srivastava K, Badami S, et al. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur J Pharmacol. 2011;654(1):100–5.CrossRefPubMed
79.
Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol. 2011;11(6):724–31.CrossRef
80.
Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-kappaB ligand and tumor cells in vitro through inhibition of the NF-kappaB cell signaling pathway. Mol Cancer Res. 2010;8(10):1425–36.CrossRefPubMedPubMedCentral
81.
Dharmapatni AA, Cantley MD, Marino V, Perilli E, Crotti TN, Smith MD, et al. The X-linked inhibitor of apoptosis protein inhibitor embelin suppresses inflammation and bone erosion in collagen antibody induced arthritis mice. Mediators Inflamm. 2015;2015:564042.CrossRefPubMedPubMedCentral
82.
Singh B, Guru SK, Sharma R, Bharate SS, Khan IA, Bhushan S, et al. Synthesis and anti-proliferative activities of new derivatives of embelin. Bioorg Med Chem Lett. 2014;24(20):4865–70.CrossRefPubMed
83.
Lu H, Wang J, Wang Y, Qiao L, Zhou Y. Embelin and its role in chronic diseases. Adv Exp Med Biol. 2016;928:397–418.CrossRefPubMed
84.
Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33–42.CrossRefPubMed
85.
Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 2000;408(6815):1004–8.CrossRefPubMed
86.
Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2016;8(339):339ra69.CrossRefPubMed
87.
Lalaoui N, Hanggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, et al. Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell. 2016;29(2):145–58.CrossRefPubMed
88.
Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, et al. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. Cell Death Dis. 2016;7:e2052.CrossRefPubMedPubMedCentral
89.
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32(28):3103–10.CrossRefPubMed
90.
Eckhardt I, Roesler S, Fulda S. Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis. 2013;4:e936.CrossRefPubMedPubMedCentral
91.
Cheung HH, Beug ST, St Jean M, Brewster A, Kelly NL, Wang S, et al. Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem. 2010;285(52):40612–23.CrossRefPubMedPubMedCentral
92.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131(4):682–93.CrossRefPubMed
93.
Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008;68(22):9384–93.CrossRefPubMedPubMedCentral
94.
95.
Muller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU, Schmuck C, et al. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS One. 2011;6(6):e21556.CrossRefPubMedPubMedCentral
96.
Mayer BA, Rehberg M, Erhardt A, Wolf A, Reichel CA, Kracht M, et al. Inhibitor of apoptosis proteins as novel targets in inflammatory processes. Arterioscler Thromb Vasc Biol. 2011;31(10):2240–50.CrossRefPubMed
97.
Lattuada D, Casnici C, Crotta K, Seneci PF, Corradini C, Truzzi M, et al. Proapoptotic activity of a monomeric smac mimetic on human fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflammation. 2015;38(1):102–9.CrossRefPubMed
98.
Lattuada D, Gualtierotti R, Crotta K, Seneci P, Ingegnoli F, Corradini C, et al. Smac127 has proapoptotic and anti-inflammatory effects on rheumatoid arthritis fibroblast-like synoviocytes. Mediators Inflamm. 2016;2016:6905678.CrossRefPubMedPubMedCentral
Metadata
Title
Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis
Authors
Bonnie Williams
Anak Dharmapatni
Tania Crotti
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 3/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-017-1116-5

Other articles of this Issue 3/2018

Inflammation Research 3/2018 Go to the issue

Original Research Paper

Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis

Original Research Paper

Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients

Review

Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases

Author Correction

Author Correction: Ouabain attenuates ovalbumin-induced airway inflammation

Original Research Paper

Mapping of the binding sites of human diamine oxidase (DAO) monoclonal antibodies

Original Research Paper

Angiotensin 1–7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits